This inventor holds 1 USPTO granted patent, plus 5 CIPO patents and 1 EPO patent. Top assignee: Cellectis S.a.. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Cecile Schiffer-Mannioui: Innovator in Cancer Therapy
Introduction
Cecile Schiffer-Mannioui is a prominent inventor based in Villiers sur Marne, France. She has made significant contributions to the field of cancer therapy through her innovative work on chimeric antigen receptors.
Latest Patents
Cecile holds a patent for "Universal chimeric antigen receptor T cells specific for CD22." This invention relates to new CD22 Chimeric Antigen Receptors (CD22 CAR), which are engineered immune cells designed to target and treat relapsed refractory CD22 expressing cancers. The engineered immune cells are particularly effective due to the incorporation of an inactivated TRAC gene.
Career Highlights
Cecile is associated with Cellectis S.A., a company known for its pioneering work in gene editing and immunotherapy. Her role at Cellectis has allowed her to focus on developing advanced therapeutic solutions for cancer patients.
Collaborations
Cecile has collaborated with notable colleagues, including Philippe Duchateau and Anne-Sophie Gautron, to further enhance the research and development of innovative cancer therapies.
Conclusion
Cecile Schiffer-Mannioui's work exemplifies the intersection of innovation and healthcare, particularly in the fight against cancer. Her contributions through patents and collaborations continue to pave the way for advancements in cancer treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile